We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03926819
Recruitment Status : Recruiting
First Posted : April 25, 2019
Last Update Posted : October 27, 2022
Sponsor:
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Hillhurst Biopharmaceuticals, Inc.

Brief Summary:
This is a single center, open label Phase 1 clinical trial in normal adult subjects to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon monoxide (CO), with single ascending doses (SAD), followed by multiple dose with doses daily for 7 days.

Condition or disease Intervention/treatment Phase
Anemia, Sickle Cell Drug: HBI-002 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Open Labeled Single Ascending Dose Followed by Multiple Dose Safety and Pharmacokinetic Study of HBI-002 Carbon Monoxide Oral Liquid Drug Product in Healthy Adult Volunteers.
Actual Study Start Date : July 25, 2022
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : February 2023

Arm Intervention/treatment
Active Comparator: Single Ascending Dose Drug: HBI-002
Oral liquid carbon monoxide drug product.

Active Comparator: Multiple Ascending Dose Drug: HBI-002
Oral liquid carbon monoxide drug product.




Primary Outcome Measures :
  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [ Time Frame: Day 1 to 7 days post last dose. ]
    Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs).

  2. Maximum COHb Concentration (Cmax). [ Time Frame: Blood samples will be drawn on Day 1 immediately before and after dosing at 30, 60, 90, 120 minutes and at 3, 4, 5, 6, 24, 48, and 72 hours ]
    Maximum COHb Concentration (Cmax).


Secondary Outcome Measures :
  1. Number of Participants With Laboratory Test Abnormalities [ Time Frame: Day 1 to 7 days post last dose. ]
    Number of Participants With Laboratory Test Abnormalities

  2. Time to Maximum COHb Concentration (Tmax). [ Time Frame: Blood samples will be drawn on Day 1 immediately before and after dosing at 30, 60, 90, 120 minutes and at 3, 4, 5, 6, 24, 48, and 72 hours ]
    Time to Maximum COHb Concentration (Tmax).

  3. Elimination Half-Life (T1/2) [ Time Frame: Blood samples will be drawn on Day 1 immediately before and after dosing at 30, 60, 90, 120 minutes and at 3, 4, 5, 6, 24, 48, and 72 hours ]
    Elimination Half-Life (T1/2)

  4. Area Under the Curve (AUC) [ Time Frame: Blood samples will be drawn on Day 1 immediately before and after dosing at 30, 60, 90, 120 minutes and at 3, 4, 5, 6, 24, 48, and 72 hours ]
    Area Under the Curve (AUC)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Signed informed consent.
  2. Healthy male or female 18-55 years of age inclusive.
  3. Negative HBsAg, aHCV, aHIV, and SARS-CoV-2 test.
  4. Non-smoker or vaper (no use of tobacco or marijuana products within 3 months of screening).
  5. Body weight between 60 kg and 110 kg (inclusive) and with BMI less than 30 kg/m2.
  6. Subjects must be healthy as defined by:

    1. absence of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic or allergic disease, as determined by the Investigator.
    2. liver function: alanine transaminase (ALT) and aspartate transaminase (AST) ≤2 times the upper limit of the normal range
    3. total bilirubin ≤1.5 times the upper limit of the normal range
    4. renal function: creatinine clearance within normal range as assessed by Cockcroft and Gault calculation
    5. carboxyhemoglobin level by venous blood gas ≤ 3.5% (any time prior to the first dose)
    6. venous lactate level <2.0 mmol/L at baseline.
    7. the absence of current clinically relevant abnormalities identified by a detailed medical history, full physical examination including blood pressure and pulse rate measurement, 12-lead ECG, and clinical laboratory tests (hematology and clinical chemistries), as determined by the Investigator.
  7. Negative pregnancy tests for females.
  8. Subjects must be willing to use a highly effective method of contraception for the duration of the study and for 30 days thereafter.

    1. Male subjects, without a vasectomy, must use a condom and be instructed that their female partner should use another form of contraception such as an IUD, diaphragm with spermicide, oral contraceptive, injectable progesterone, subdermal implant or a tubal ligation if the female partner could become pregnant
    2. Female subjects of childbearing potential (not surgically sterilized and less than one year post-menopausal) should use a form of contraception such as an IUD, diaphragm with spermicide, oral contraceptive, injectable progesterone, subdermal implant or a tubal ligation, and be instructed that their male partners should use a condom, if not vasectomized.

Exclusion Criteria:

Subjects who meet any of the following criteria will be ineligible for participation in the study:

  1. Subjects with concurrent illness/disease as defined by:

    1. clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic or allergic disease, as determined by the Investigator.
    2. current clinically relevant abnormalities identified by a detailed medical history, full physical examination including blood pressure and pulse rate measurement, 12-lead ECG, and clinical laboratory tests (hematology, clinical chemistries and urinalysis), as determined by the Investigator.
    3. clinically significant illness and/or surgery within 4 weeks prior to dosing.
  2. Anemia of any cause.
  3. Homozygous or heterozygous hemoglobinopathy.
  4. Blood transfusion within six weeks prior to the first administration of study drug.
  5. Carboxyhemoglobin ≥ 3.5% (any time prior to the first dose)
  6. Oxygen saturation by transcutaneous measurement consistently ≤ 95% (any time prior to the first dose)
  7. Exposure to any live vaccine within 28 days prior to study drug administration.
  8. History of febrile or infective illness within 14 days prior to dosing.
  9. Positive pregnancy test or breast feeding for females.
  10. Weight loss or gain of more than 5 kg within 3 months prior to dosing.
  11. History of alcohol abuse or dependence or regular use of alcohol within six months prior to dosing (defined as more than 14 units of alcohol per week; 1 Unit= 150 mL wine, 360 mL beer or 45 mL of 40% alcohol)
  12. Positive result on alcohol screen
  13. History of pulmonary infiltrate or pneumonia within 6 months prior to dosing or pulmonary/bronchial infection within 2 weeks prior to dosing.
  14. History of cancer, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin more than 1 year prior.
  15. History of cardiac disease
  16. History of drug abuse or dependence.
  17. Positive results on drug screen (oxycodone, benzodiazepines, THC, cocaine, opiates, and methamphetamine).
  18. Use of prescription drugs within 7 days or 5 half-lives (whichever is longer) prior to dosing. Herbal and vitamin supplements must be discontinued 14 days prior to dosing.
  19. Unwilling or unable to comply with the requirements of the protocol.
  20. Treatment with an investigational drug within the longer of 30 days or five half-lives.
  21. Systolic blood pressure lower than 90 or above 140 mm Hg, diastolic blood pressure lower than 50 or above 90 mm Hg, heart rate less than 45 or above 100 bpm, or arrhythmia at screening and/or baseline. ECG abnormalities or other vital sign abnormalities that are clinically significant at screening and/or baseline, as determined by the Investigator.
  22. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into the study.
  23. History of allergic reactions to any of the drug product excipients
  24. History of epilepsy or seizure
  25. History of suicide attempts or ideation (by medical history)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03926819


Contacts
Layout table for location contacts
Contact: Contact Company 858 232 9495 hillhurstinfo@hillhurstbio.com

Locations
Layout table for location information
United States, California
Contact Company Recruiting
San Diego, California, United States, 92121
Sponsors and Collaborators
Hillhurst Biopharmaceuticals, Inc.
National Heart, Lung, and Blood Institute (NHLBI)
Layout table for additonal information
Responsible Party: Hillhurst Biopharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03926819    
Other Study ID Numbers: HBI-CP-01-001
2R44HL131065 ( U.S. NIH Grant/Contract )
First Posted: April 25, 2019    Key Record Dates
Last Update Posted: October 27, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Hillhurst Biopharmaceuticals, Inc.:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn
Carbon Monoxide
CO
Heme Oxygenase
HO-1
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia
Anemia, Sickle Cell
Hematologic Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hemoglobinopathies
Genetic Diseases, Inborn